Raymond James Financial
APLS

Raymond James Financial’s Apellis Pharmaceuticals APLS Stock Holding History

Raymond James Financial’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,631
Closed -$2.52M – 5404
2026
Q1 		$2.52M Sell
62,631
-4,366
-7% -$94.1K ﹤0.01% 3171
2025
Q4 		$1.68M Sell
66,997
-10,681
-14% -$251K ﹤0.01% 3402
2025
Q3 		$1.76M Buy
77,678
+3,212
+4% +$74.9K ﹤0.01% 3264
2025
Q2 		$1.29M Buy
74,466
+22,488
+43% +$416K ﹤0.01% 3402
2025
Q1 		$1.14M Buy
51,978
+2,963
+6% +$81.9K ﹤0.01% 3391
2024
Q4 		$1.56M Buy
+49,015
New +$1.47M ﹤0.01% 3143

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Raymond James Financial's APLS Position: Q2 2026 in Review

Raymond James Financial sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 62,631 shares — an estimated $2.52M sold.

Raymond James Financial first reported a position in APLS in Q4 2024 and held it in 6 quarters. The position peaked at $2.52M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Raymond James Financial reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 62,631 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.52M.
  • Raymond James Financial first reported a position in Apellis Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Raymond James Financial's Apellis Pharmaceuticals position peaked at $2.52M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.